Shared REMS: US FDA Wants Brisk Brand-Generic Talks, Might Give Unilateral Waivers

New draft guidances are an attempt to curb abuse of REMS single shared system process to delay generic entry.

FDA entrance sign 2016

The US FDA expects that shared system REMS negotiations should last no more than five months, and dangled the possibility of unilaterally issuing a waiver to the generic sponsor if the talks don't move fast enough.

Two new guidances on single shared system Risk Evaluation and Mitigation Strategies issued May 31 are intended to help eliminate...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet